{
    "nct_id": "NCT04305145",
    "official_title": "Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor Colitis",
    "inclusion_criteria": "* Age â‰¥ 18\n* Stage III/IV skin cancer\n* Treatment with CTLA-4 inhibitor alone or in combination with PD-1or PD-L1 blockade within the past 8 weeks\n* Clinically significant diarrhea resulting in the decision to pause immunotherapy treatment\n* Endoscopically visible colitis (Mayo 1-3) at the time of screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior history of inflammatory colitis related to immune checkpoint inhibitors requiring treatment with > 10 mg/day of prednisone or equivalent, or any other immunosuppressive medication\n* Concurrent immune-related Adverse Event (irAE) requiring treatment with systemic corticosteroids (dose equivalent of prednisone 10 mg/day or higher) or another systemic immune suppressing medication within the past 10 days\n* Current use of any immune suppressing biologic medication, or use within the last 4 weeks; immune stimulating medications such as checkpoint blockade are explicitly permitted\n* Current use of combination treatment with an investigation immunotherapy targeting a pathway other than PD-1 or PD-L1, concurrent chemotherapy, or targeted therapy\n* Previous adverse reaction to infliximab or corticosteroids\n* Colonic perforation or abscess present at the time of screening\n* History of Hepatitis B or C with a positive viral load, untreated mycobacterium tuberculosis, or active herpes zoster infection\n* Current bacterial infection requiring antibiotic treatment, or systemic fungal infection\n* Prior history of inflammatory bowel disease, microscopic colitis or segmental colitis associated with diverticulosis\n* Received more than 3 doses of systemic corticosteroids, or receive dsystemic corticosteroids at a dose exceeding 2mg/kg methylprednisolone or equivalent, within 72 hours prior to endoscopy",
    "miscellaneous_criteria": ""
}